HOUSTON, Jan. 23, 2024 /PRNewswire/ -- Nutex Health Inc. ('Nutex Health' or the 'Company') (NASDAQ: NUTX), today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor whereby the investor has agreed to purchase 66,666,666 shares of common stock and warrants to purchase up to an aggregate of 66,666,666 shares of common stock at a purchase price of $0.15 per share and accompanying warrant in a registered direct offering.

休斯顿，2024年1月23日/PRNewswire/--Nutex Health Inc.（“Nutex Health”或“公司”）（纳斯达克：NUTX），今天宣布，它已与一家专注于医疗保健的机构投资者签订了证券购买协议，根据该协议，该投资者同意购买666666股普通股和认股权证，以每股0.15美元的购买价格购买总计666666股普通股，并在登记的直接发售中购买附带的认股权证。

The warrants have an exercise price of $0.15 per share, are exercisable immediately, and will expire five years following the date of issuance..

认股权证的行权价格为每股0.15美元，可立即行权，并将在发行日期后五年到期。。

Maxim Group LLC is acting as the sole placement agent in connection with the offering.

Maxim Group LLC是此次发行的唯一配售代理。

The gross proceeds to Nutex Health are estimated to be $10.0 million before deducting the placement agent fees and other offering expenses. The offering is expected to close on or about January 25, 2024, subject to the satisfaction of customary closing conditions.

在扣除配售代理费和其他发行费用之前，Nutex Health的总收益估计为1000万美元。预计本次发行将于2024年1月25日左右结束，但须符合惯例的结束条件。

The offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-270886) previously filed with the U.S. Securities and Exchange Commission ('SEC'), which was declared effective on April 7, 2023. The securities may be offered only by means of the prospectus supplement and the accompanying prospectus that form a part of the registration statement.

本次发行是根据先前向美国证券交易委员会（“SEC”）提交的表格S-3（文件号333-270886）上的有效货架登记声明进行的，该声明于2023年4月7日宣布生效。证券只能通过补充招股说明书和构成登记声明一部分的随附招股说明书进行发售。

Copies of the final prospectus supplement and accompanying prospectus relating to the registered direct offering may be obtained, when available, by contacting Maxim Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Prospectus Department, or by telephone at (212) 895-3745 or by email at [email protected].

可通过联系Maxim Group LLC（地址：300 Park Avenue，16th Floor，New York，NY 10022）联系Maxim Group LLC（地址：300 Park Avenue，16th Floor，New York，NY 10022，收件人：招股说明书部门）或通过电话（212）895-3745或电子邮件[受电子邮件保护]获取与注册直接发售相关的最终招股说明书补充文件和随附招股说明书的副本。

A final prospectus supplement related to the offering will be filed with the SEC and will be available free of charge by visiting EDGAR on the SEC's website at www.sec.gov..

与本次发行相关的最终补充招股说明书将提交给美国证券交易委员会，并可通过访问美国证券交易委员会网站www.SEC.gov上的EDGAR免费获得。。

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

本新闻稿不构成出售或招揽购买这些证券的要约，也不构成在根据任何州或其他司法管辖区的证券法注册或取得资格之前，在任何州或其他司法管辖区出售这些证券都是非法的。

Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended..

任何要约、招揽或要约购买或任何证券销售都将根据经修订的《1933年证券法》的登记要求进行。。

About Nutex Health Inc.:

关于Nutex Health Inc.：

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

Nutex Health Inc.（纳斯达克股票代码：NUTX）总部位于德克萨斯州休斯顿，成立于2011年，是一家医疗保健管理和运营公司，下设两个部门：医院部门和人口健康管理部门。

Forward-Looking Statements

前瞻性声明

Certain statements and information included in this press release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases 'will', 'will likely result,' 'expected to,' 'expects to,' 'will continue,' 'anticipated,' 'estimate,' 'projected,' 'intend,' 'goal,' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995.

本新闻稿中的某些声明和信息构成1995年《私人证券诉讼法》所指的“前瞻性声明”。当在本新闻稿中使用“将”、“可能产生”、“预期”、“预期”、“将继续”、“预期”、“估计”、“预计”、“打算”、“目标”或类似词语时，旨在识别1995年《私人证券诉讼改革法》所指的“前瞻性声明”。

Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company.  Such uncertainties and risks include, but are not limited to, the satisfaction of customary closing conditions, our ability to successfully execute our growth strategy, changes in laws or regulations, including final rules implemented under the No Surprises Act and related regulatory guidance, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing.

此类报表存在某些已知和未知的风险以及不确定性，其中许多风险超出了公司的控制范围。此类不确定性和风险包括但不限于满足常规交割条件、我们成功执行增长战略的能力、法律或法规的变化，包括根据《不出人意料法案》和相关监管指南实施的最终规则、经济状况、对管理层的依赖、股东稀释、资本缺乏，快速增长对公司的影响，以及管理层有效应对公司产品和服务的增长和需求的能力，新开发的技术，公司的竞争能力，关联方交易中的利益冲突，监管事项，技术保护，缺乏行业标准，竞争的影响和公司获得未来融资的能力。

An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2022 and the Current Reports on Form 10-Q for the periods ended March 20, 2023, June 30, 2023, and September 30, 2023 under the heading 'Risk Factors' in Part I, Item IA thereof,.

表10-K中截至2022年12月31日的年度报告和表10-Q中截至2023年3月20日、2023年6月30日和2023年9月30日的当期报告在第一部分第IA项“风险因素”标题下讨论了可能影响未来结果的广泛因素，。

SOURCE Nutex Health, Inc.

来源Nutex Health，Inc。